NOVEL COMPOUNDS

Abstract: Novel pyridin-4-yl or pyrimidin-4-yl substituted pyridine compounds and compositions for use in therapy.

Description: NOVEL COMPOUNDS FIELD OF THE INVENTION This invention relates to novel pyridine substituted compounds, processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and pharmaceutical compositions for use in such therapy. BACKGROUND OF THE INVENTION Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)]. Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine / threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [Hunter, T.. Methods in Enzvmologv (Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991]. For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell, 80, 179 (1995); Herskowitz, I. Cell . 80, 187 (1995); Hunter, T. Cell , 80, 225 (1995);Seger, R., and Krebs, E. G. FASEB J., 726-735 (1995)]. While many signaling pathways are part of cell homeostasis, numerous cytokines (e.g., IL-1 and TNF) and certain other mediators of inflammation (e.g., COX-2, and iNOS) are produced only as a response to stress signals such as bacterial lippopolysaccharide (LPS). The first indications suggesting that the signal transduction pathway leading to LPS -induced cytokine biosynthesis involved protein kinases came from studies of Weinstein [Weinstein, et al., J. Immunol. 151, 3829(1993)] but the specific protein kinases involved were not identified. Working from a similar perspective, Han [Han, et al., Science 265, 808(1994)] identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS. Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee; et al., Nature. 372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents. The discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti- inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL-1 and TNF synthesis in human monocytes at concentrations in the low uM range [Lee, et al., Int. J. Immunopharmac. 10(7), 835(1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee; et al.. Annals N. Y. Acad. Sci.. 696, 149(1993)]. It is now firmly established that CSBP/p38 is a one of several kinases involved in a stress-response signal transduction pathway which is parallel to and largely independent of the analogous mitogen-activated protein kinase (MAP) kinase cascade (Figure 1). Stress signals, including LPS, pro-inflammatory cytokines, oxidants, UV light and osmotic stress, activate kinases upstream from CSBP/p38 which in turn phosphorylate CSBP/p38 at threonine 180 and tyrosine 182 resulting in CSBP/p38 activation. MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp 27 (Figure 2). It is not yet known whether MAPKAP-2, MAPKAP-3, Mnkl or Mnk2 are involved in cytokine biosynthesis or alternatively that inhibitors of CSBP/p38 kinase might regulate cytokine biosynthesis by blocking a yet unidentified substrate downstream from CSBP/p38 [Cohen, P. Trends Cell Biol., 353-361(1997)]. What is known, however, is that in addition to inhibiting IL-1 and TNF, CSBP/p38 kinase inhibitors (SK&F 86002 and SB 203580) also decrease the synthesis of a wide variety of pro-inflammatory proteins including, IL-6, IL-8, GM-CSF and COX-2. Inhibitors of CSBP/p38 kinase have also been shown to suppress the TNF- induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the IL-1 -stimulated synthesis of collagenase and stromelysin. These and additional data demonstrate that CSBP/p38 is involved not only cytokine synthesis, but also in cytokine signaling [CSBP P38 kinase reviewed in Cohen, P. Trends Cell Biol., 353-361(1997)]. Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels. There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent evidence also links IL-1 activity to diabetes and pancreatic β cells [review of the biological activities which have been attributed to IL-1 Dinarello, J. Clinical Immunology, 5 (5), 287-297 (1985)]. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resoφtion diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis. Interleukin-8 (IL-8) is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL-1, TNF, or lipopolysachharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac- 1 (CDl lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions associated with an increased in IL-8 production (which is responsible for chemotaxis of neutrophil into the inflammatory site) would benefit by compounds which are suppressive of IL-8 production. IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states. Inhibition of signal transduction via CSBP/p38, which in addition to IL-1, TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (i.e., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for CSBP/p38 kinase inhibitors [Badger, et al, J. Pharm. Exp. Thera. 279 (3): 1453- 1461.(1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996)]. There remains a need for treatment, in this field, for compounds which are cytokine suppressive anti-inflammatory drugs, i.e. compounds which are capable of inhibiting the CSBP/p38/RK kinase. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 demonstrates the mitogen-activated protein kinase (MAP) kinase cascade. Figure 2 demonstrates the p38 kinase pathway. SUMMARY OF THE INVENTION This invention relates to the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutically acceptable diluent or carrier. This invention relates to a method of treating a CSBP/RK/p38 kinase mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I). This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I). This invention more specifically relates to a method of inhibiting the production of IL- 1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I). This invention more specifically relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I). This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I). Accordingly, the present invention provides for a compound of the formula : wherein R is hydrogen, X-R a , optionally substituted Cι_4 alkyl, halogen, hydroxyl, optionally substituted C1.4 alkoxy, optionally substituted Cι _4 alkylthio, optionally substituted Cj_4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci .g alkyl substituted amino, N(Rio)C(O)Rb, N(Rio)S(O)2 d > or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; Y is CH or N; X is oxygen, sulfur or NH; R a is C\_β alkyl, aryl, arylCι_6 alkyl, heterocyclic, heterocyclylCi _g alkyl, heteroaryl, or heteroarylCi .5 alkyl moiety, wherein each of these moieties may be optionally substituted; Rtø is hydrogen, Cι _ alkyl, C3..7 cycloalkyl, aryl, arylCι.4 alkyl, heteroaryl, heteroarylCi .4 alkyl, heterocyclyl, or heterocyclylCι_4 alkyl; R f j is Cj_ alkyl, C3.7 cycloalkyl, aryl, arylCι _4 alkyl, heteroaryl, heteroarylCi .4 alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl; n is 0, or an integer having a value of 1 to 10; v is 0, or an integer having a value of 1 or 2; m is 0, or the integer having a value of 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; R2, R3 and R5, are independently hydrogen, (CRI QR23) Π OR9, (CRκ)R23)nORl l' Cι_ιo alkyl, halo-substituted C J. I Q alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C3_7cycloalkylC ι o alkyl, C5.7 cycloalkenyl, C5.7 cycloalkenyl Cι_ιo alkyl, aryl, arylCι _ιo alkyl, heteroaryl, heteroarylCi. \Q alkyl, heterocyclyl, heterocyclylC I .I Q alkyl, (CRιoR-23)nS(O) m Rιg, (CRi 0 R23)nNHS(O) 2 Ri8, (CRι 0 R23)nNRi3Rl4* (CRι 0 2 3)n O 2 , (CR 10 R 2 3)nCN, (CR 10 R 2 3)n S(O)m li 3Ri4, (CR 10 R 2 3)nC(Z)Rι ι, (CRιoR 2 3)nOC(Z)Rπ , (CR 10 R 2 3)nC(Z)OR 1 1 , (CRιoR23)nC(Z)NR 13 R 14) (CR 10 R 2 3)nC(Z)NRι 1 OR9, (CR 10 R 2 3)nNRiθC(Z)Rι 1 , (CR 10 R23)nNRloC(Z)NR 1 3R 1 4, (CR 1 oR23)nN(OR 6 )C(Z)NR 1 3R 14 , (CRι 0 R 2 3)nN(OR 6 )C(Z)Rι 1, (CR 10 R 3)nC(=NOR 6 )R 1 h (CR 10 R 2 3)nNRlθC(=NR 19 ) NR 13 R 14 , (CR 10 R23)nOC(Z)NR 13 Ri4, (CR 10 R 2 3)nNRlθC(Z) NR 13 R 14 , (CRιoR 2 3)nNRlθC(Z)OR 10 , 5-(Rι 8 )-l,2,4- oxadizaol-3-yl or 4-(Rι 2)-5-(RjgRi9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; and wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or heteroaryl, which is optionally substituted by one to three substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri 7, C(Z)ORι g, (CRIQR20) V ORI2, SR5', S(O)R5>, OR12, halo-substituted-Cι.4 alkyl, Chalky!, ZC(Z)R]2, NR 10 C(Z)Ri6, or (CRιoR2θ) vNR 10 R 20 and which, for other positions of substitution, is halogen, cyano, nitro, phenyl, C(Z)NRι 3R14, C(Z)OR 5, (CR 1 oR2θ)m"COR25, S(O) m R 2 5, OR25, halosubstituted-Cι.4 alkyl, C I .I Q alkyl, ZC(Z)R25, optionally substituted phenyl, (CR 10 R2θ)m " NRlθC(Z)R 25 , NRι 0 S(O) m >R 8 , NRι 0 S(O) m' NR 7 Rι 7 , or ( CR 10 R 2 0)m"NRl3Rl4; R5' is hydrogen, C1.4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5' being SNR7R17 and SOR5' being SOH; R6 is hydrogen, a pharmaceutically acceptable cation, Ci _\Q alkyl, Cι,- cycloalkyl, aryl, arylCι _4 alkyl, heteroaryl, heteroarylCi .4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R17 is each independently selected from hydrogen or C 1.4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; Rg is C1.10 alkyl, halo-substituted C I_ I Q alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C5.7 cycloalkenyl, aryl, arylC j .i o alkyl, heteroaryl, heteroarylC ι_ι o alkyl, (CR 10 R 2 θ)nORl l, (CRi ()R2θ)nS(O) m Rι 8 , (CRι 0 R2θ)n HS(O) 2 Rιg, or (CRιoR2θ)nNRl3Rl4. wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted; R9 is hydrogen, C(Z)Rι 1 or optionally substituted C J . I Q alkyl, S(O)2Ri8, optionally substituted aryl or optionally substituted arylCι .4 alkyl; Rio and R20 is each independently selected from hydrogen or C1.4 alkyl; R\ 1 is hydrogen, C\_\Q alkyl, 03.7 cycloalkyl, heterocyclyl, heterocyclyl C1.1 alkyl, aryl, alkyl, heteroaryl or a heteroarylC 1 _I Q alkyl moiety, wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl or heterocyclylalkyl moieties may be optionally substituted; R12 is hydrogen or Rjg; R13 and R14 is each independently selected from hydrogen or optionally substituted C1.4 alkyl, optionally substituted aryl or optionally substituted aryl-C 1- alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; R15 is hydrogen, Cι _4 alkyl or C(Z)-Cι _4 alkyl; R\ is Cι _4 alkyl, halo-substituted-Cι .4 alkyl, or C3..7 cycloalkyl; Ri g is Cι _ιo alkyl, C3.7 cycloalkyl, heterocyclyl, aryl, arylCι _ιo alkyl, heterocyclyl, heterocyclyl-Cι _i alkyl, heteroaryl or a heteroarylalkyl moiety, wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl or heterocyclylalkyl moieties may be optionally substituted; R19 is hydrogen, cyano, C1.4 alkyl, C3.7 cycloalkyl or aryl; R23 is hydrogen, Cj.g alkyl, 03.7 cycloalkyl, aryl, arylCι .4 alkyl, heteroaryl, heteroarylC 1 -4 alkyl, heterocyclyl, or a heterocyclylC 1.4 alkyl moiety, all of which moieties may be optionally substituted; R25 is heterocyclyl, heterocyclylC \. Q alkyl or Rg; 1 - Z is oxygen or sulfur; or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE INVENTION The novel compounds of Formula (I) herein may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of cytokine inhibition or production. In particular, cytokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections. In compounds of Formula (I), suitable R\ moieties include hydrogen, XRa, optionally substituted Ci-4 alkyl, halogen, hydroxyl, optionally substituted Cι_4 alkoxy, optionally substituted C]-4 alkylthio, optionally substituted Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rιo)C(O)R D ; N(Rιo)S(O)2Rd. or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15. Preferably Rl is other than hydrogen. Suitably Y is oxygen or sulfur or NH, preferably oxygen or NH. Suitably, R a is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylC 1 -6 alkyl, heteroaryl, or heteroarylC i-βalkyl, wherein each of these moieties may be optionally substituted as defined herein. When the substituent is YR a , and Ra is preferably aryl, such as phenyl or naphthyl. When the substituent is YR a , and R a is heterocyclic, it is preferably pyrrolindinyl, piperidine, morpholino, tetrahydropyran, tetrahydrothiopyranyl, tetrahydrothipyran-sulfinyl, tetrahydrothio-pyransulfonyl, pyrrolindinyl, indole, or piperonyl. It is noted that the heterocyclic rings herein may contain unsaturation, such as in a tryptamine ring. When the substituent is YR , and R a is heteroaryl, it is pyrrole, quinoline, furan, thienyl, pyrazole, isoquinoline, pyridine, pyrimidine, pyridazine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole. These R a aryl, heterocyclic and heteroaryl rings may also be optionally substituted one or more times, suitably 1 to 4 times, independently with halogen; C]_4 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl ; hydroxy; -4 alkoxy, such as methoxy or ethoxy; S(0) m alkyl and S(0)m aryl (wherein m is 0, 1, or 2); C(0)ORj3, such as C(0)Cι_4 alkyl or C(0)OH moieties; C(0)Rj3; OC(0)R c ; 0-(CH2)s-0-, and s is an integer of 1 to 3, such as in a ketal or dioxyalkylene bridge; NR7R17; N(R]0)C(O)Rb; C(O)NRi()R20; cyano, nitro, or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; C]-6 alkyl substituted one or more times independently with halogen (such as CF3), hydroxy, alkoxy, C(0)OR 13 , -0(0)CR 13 , R7R17, C(0)NR7Rπ, C(0)R 13 , or NHC(0)Rj3; optionally subtituted aryl, such as phenyl; optionally substituted arylalkyl, such as benzyl or phenethyl; aryloxy, such as phenoxy; or arylalkyloxy such as benzyloxy; and wherein these aryl,arylalkyl, aryloxy and arylalkyloxy moieties may themselves be optionally substitued with halogen, alkyl, alkoxy, S(0)m alkyl, amino, or mono- and di-Cι_6 alkylsubstituted amino. Suitably, R is hydrogen, Ci-6 alkyl, C3 -7 cycloalkyl, aryl, arylCι- 4 alkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl, wherein all of which may be optionally substituted. Suitably, R c is hydrogen, optionally substituted Ci-6 alkyl, C3-.7 cycloalkyl, aryl, arylCι_ 4 alkyl, heteroaryl, heteroarylC i_4alkyl, heterocyclyl, or heterocyclylC ι_4 alkyl moiety, wherein all of which may be optionally substituted. Suitably, Rd is C 1-6 alkyl, 03. 7 cycloalkyl, aryl, arylCι_ 4 alkyl, heteroaryl, heteroarylC i-4alkyl, heterocyclyl, or heterocyclylC ι_4 alkyl, wherein all of which may be optionally substituted. When the R a moiety is an alkyl group it may be optionally substituted as defined herein. Also the alkyl portion of the Ri substituents, the mono- and di-Ci-6 alkyl amino moieties, may also be halo substituted. Preferably, the R a group is an alkyl, such as methyl, an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl. When the Ri substituent group is N(Rιo)C(O) Rb, Rb is preferably a Ci-6 alkyl; and Rio is preferably hydrogen. It is also recognized that all the Rb moieties, in particular the Ci-6 alkyl group may be optionally substituted, preferably from one to three times as defined herein. Preferably Rb is Ci-6 alkyl substituted with halogen, such as fluorine, as in trifluoromethyl or trifluroethyl. Suitably, R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl ring. Preferably R4 is a phenyl or naphthyl ring. Suitably, R4 is optionally substituted by one to three substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth- 2-yl or 6-naphth-2-yl or heteroaryl substituent, is halogen, cyano, nitro, C(Z)NR 7 Ri 7 , C(Z)OR 16 , (CRι 0 R 2 θ) V CORι 2 , SR 5 % S(O)R 5 >, OR 12 , halo-substituted-Cι_4 alkyl, Ci^alkyl, ZC(Z)Rι 2 , NRκ)C(Z)Ri6, or (CRIQ 2 O) V NRIOR 2 0 an(J which, for other positions of substitution, is halogen, cyano, nitro, phenyl, C(Z)NRι 3 Rι 4 , C(Z)OR 25 , (CR 10 R 2 o)m"COR 25 , S(O) m R 25 , OR 2 5, halosubstituted-Cj.4 alkyl, C\.\ alkyl, ZC(Z)R 2 5, optionally substituted phenyl, (CRι 0 R 20 ) m" NR 10 C(Z)R 25 , NRι 0 S(O) m' Rg, NRι 0 S(O) m' NR 7 R 17 , or (CRιoR 2 θ ) m"NRl3Rl4- Preferably, for the 4-position on the phenyl ring and the naphth-1-yl, the substituents are selected from halogen, SR5', SOR5', OR12, CF3, or (CRιoR 2 θ)vNRlθR 2 0> and for other positions of substitution on these rings preferred substitution is halogen, S(O) m R 2 5, OR 2 5, CF3, (CRioR 2 0)m"NRl3Rl4, NRιoC(Z)R 25 or NRιoS(O)m'Rg. More preferred substituents for the 4-position in the phenyl and naphth-1-yl and on the 5 -position in naphth-2-yl include halogen, especially fluoro and chloro, and SR5' and SOR5' wherein R5' is preferably a Cι_ 2 alkyl, more preferably methyl; of which the fluoro and chloro is more preferred, and most especially preferred is fluoro. For all other substituents, in particular for the 3-position in phenyl and naphth-1-yl rings, the substituents are independently selected from halogen, especially fluoro and chloro; OR25, especially Ci-4 alkoxy; CF3, NRιoR20 > such as amino; NRi()C(Z)R25, especially NHCO(Ci-K) alkyl); NRioS(O) m 'R8, especially NHSO2(Ci-io alkyl); and SR25 and SOR25 wherein R25 is preferably a Ci-2 alkyl, more preferably methyl. When the phenyl ring is disubstituted, preferably it is two independent halogen moieties, such as fluoro and chloro, preferably di-chloro and more preferably in the 3, 4-position. It is also preferred that for the 3-position of both the OR25 and ZC(Z)R25 moieties, that the R 2 5 may also include hydrogen. Preferably, the R4 moiety is an unsubstituted or substituted phenyl moiety. More preferably, R4 is phenyl or phenyl substituted at the 4-position with fluoro and/or substituted at the 3-position with fluoro, chloro, Ci-4 alkoxy, methanesulfonamido or acetamido, or R4 is a phenyl di-substituted at the 3,4- position independently with chloro or fluoro, more preferably chloro. Most preferably, R4 is 4-fluorophenyl. In Formula (I), R 2 5 is heterocyclyl, heterocyclylC \.\Q alkyl or Rg; In Formula (I), Z is suitably oxygen or sulfur. Suitably, R 2 , R3 and R5 are independently selected from hydrogen, (CRιoR 2 3)nOR9, (CRιoR 2 3)nORπ, Ci-ioalkyl, halo-substituted Cι-10 alkyl, C 2 -io alkenyl, C 2 -10 alkynyl, C3.7 cycloalkyl, C3-7cycloalkylCi-io alkyl, C5..7 cycloalkenyl, C5.7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylC i-ioalkyl, heterocyclyl, heterocyclylC i- 10 alkyl, (CRιoR 2 3)nS(O) m Rιg, (CRι 0 R 2 3)nNHS(O) 2 Rι 8 , (CRι 0 R 2 3)nNRl3Rl4. (CRlθR23)nNO 2 , (CRι 0 R23)nCN, (CRιoR23)nS(O) m 'NRι 3 Rι 4 , (CRioR230)nC(Z)Rn, (CRιoR23)nOC(Z)Rn, (CRι 0 R23)nC(Z)ORn, (CRιoR23)nC(Z)NRι 3 Rl4, (CRιoR 2 3)nC(Z)NRι ιOR 9 , ( CRιoR23)nNRiθC(Z ) Rι ι, ( CRιoR23)nNRlθC ( Z)NRι 3 Rl4, (CRιoR23)nN(OR6)C(Z)NRι 3 Rl4, (CRi 0 R23)nN(OR 6 )C(Z)Rι 1, ( CRιoR23)nC(=NOR6 ) Rl l, ( CRιoR23)nNRlθC ( =NRl9)NRl3 l4, ( CRιoR23)nOC(Z)NRi 3 Rl4, (CRlθR23)nNRlθC(Z)NRι 3 Rl4, (CRιoR23)nNRlθC(Z)ORιo, 5-(Rι 8 )-l,2,4-oxadizaol-3-yl or 4-(Rι 2 )-5-(Rι 8 Rι 9 )- 4,5-dihydro-l,2,4-oxadiazol-3-yl; wherein the cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted. Suitably, R 2 3 is hydrogen, Cι_6 alkyl, C3..7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylC ι_4alkyl, heterocyclyl, or heterocyclylC 1.4 alkyl moiety, all of which may be optionally substituted as defined below. Preferably, R 2 , R3 and R5 are hydrogen, an optionally substituted heterocyclyl ring, and optionally substituted heterocyclylC i- 10 alkyl, an optionally substituted Ci-i alkyl, an optionally substituted C3-7cycloalkyl, an optionally substituted C3_7cycloalkyl Ci-io alkyl, (CRιoR 2 3)nC(Z)ORι 1 group, (CRιoR 2 3)nNRl3Rl4, (CRι 0 R 3)nNHS(O) 2 Rιg, (CRι 0 R 2 3)nS(O) m Rιg, an optionally substituted aryl; an optionally substituted arylCi-io alkyl, (CRιoR23)nORl 1, (CRι 0 R 2 3)nC(Z)Rι 1, or (CRι 0 R 2 3)nC (=NOR6)Rl 1 group. Preferably, R 2 , R3 and R5 are selected from hydrogen, Ci-io alkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylC 1- 10 alkyl, (CRιoR 2 3)nNS(O) Rιg, (CRι 0 R 2 3)nS(O) m Rιg, arylCi-io alkyl, (CRioR 2 3)n Rl3Rl4, optionally substituted C3-7cycloalkyl, or optionally substituted C3-7cycloalkyl Ci-io alkyl. When R 2 , R3 and R5 are an optionally substituted heterocyclyl, the ring is preferably a moφholino, pyrrolidinyl, or a piperidinyl group. When the ring is optionally substituted, the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself. Preferably the ring is a piperidine or pyrrole, more preferably piperidine. The heterocyclyl ring may be optionally substituted one to four times independently by halogen; Ci-4 alkyl; aryl, such as phenyl; aryl alkyl, such as benzyl, wherein the aryl or aryl alkyl moieties themselves may be optionally substituted (as in the definition section below); C(O)ORι 1, such as the C(O)Cι_4 alkyl or C(O)OH moieties; C(O)H; C(O)Cj-4 alkyl, hydroxy substituted Ci-4 alkyl, Ci-4 alkoxy, S(O) m Ci-4 alkyl (wherein m is 0, 1, or 2), NR10R2O (wherein Rio and R 2 o are independently hydrogen or Cι-4alkyl). Preferably if the ring is a piperidine, the substituents are directly attached on the available nitrogen, i.e. a l-Formyl-4-piperidine, l-benzyl-4-piperidine, 1-methyl- 4-piperidine, l-ethoxycarbonyl-4-piperidine. If the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2- or 6- position or both, such as 2,2,6,6-tetramethyl-4-piperidine. When R 2 , R3 and R5 are an optionally substituted heterocyclyl Ci-io alkyl group, the ring is preferably a moφholino, pyrrolidinyl, or a piperidinyl group. Preferably this alkyl moiety is from 1 to 4, more preferably 3 or 4, and most preferably 3, such as in a propyl group. Preferred heterocyclic alkyl groups include but are not limited to, moφholino ethyl, moφholino propyl, pyrrolidinyl propyl, and piperidinyl propyl moieties. When R , R3 and R5 are an optionally substituted C3-7cycloalkyl, or an optionally substituted C3_7cycloalkyl Ci-io alkyl, the cycloalkyl group is preferably a C4 or Cfr ring, most preferably a C6 ring, which ring is optionally substituted. The cycloalkyl ring may be optionally substituted one to three times independently by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; OC(O)Rb, Ci-io alkoxy, such as methoxy or ethoxy; S(O) m alkyl, wherein m is 0, 1, or 2, such as methylthio, methylsulfinyl or methylsulfonyl; S(O) m aryl; cyano, nitro, amino, mono & di-substituted amino, such as in the NR7R17 group, wherein R7 and R17 are as defined in Formula (I), or where the R7R17 may cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from oxygen, sulfur or NR15; N(Rιo)C(O)Xι and Xi is Ci-4 alkyl, aryl or arylCi-4alkyl; Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; optionally substituted alkyl wherein the substituents are halogen, (such as CF3), hydroxy, nitro, cyano, amino, mono & di- alkyl substituted amino, such as in the NR7R17 group, S(O)m alkyl and S(O)m aryl, wherein m is 0, 1 or 2; optionally substituted alkylene, such as ethylene or propylene; optionally substituted alkyne, such as ethyne; C(O)OR \, such as the free acid or methyl ester derivative; the group R e ; C(O)H; =O; =N-ORι 1; N(H)-OH (or substituted alkyl or aryl derivatives thereof on the nitrogen or the oxime moiety); N(ORf)-C(O)-R 2 ; an optionally substituted aryl, such as phenyl; an optionally substituted arylCi-4alkyl, such as benzyl of phenethyl; an optionally substituted heterocycle or heterocyclic Ci-4alkyl, and further these aryl, arylalkyl, heterocyclic, and heterocyclic alkyl moieties are optionally substituted one to two times by halogen, hydroxy, Ci-io alkoxy, S(O) m alkyl, cyano, nitro, amino, mono & di- substituted amino, such as in the NR7R17 group, an alkyl, or an halosubstituted alkyl. Suitably R e is a 1,3-dioxyalkylene group of the formula -O-(CH 2 )s-O-, wherein s is 1 to 3, preferably s is 2 yielding a 1 ,3-dioxyethylene moiety, or ketal functionality. Suitably Rf is hydrogen, a pharmaceutically acceptable cation, aroyl or a Ci-io alkanoyl group. Suitably R21 is NR2 2 R 2 4; alkyl j.g; halosubstituted alkyl ι_6; hydroxy substituted alkyl \. ; alkenyl 2-6 . aryl or heteroaryl optionally substituted by halogen, alkyl ι_6 ) halosubstituted alkyl 1 -6, hydroxyl, or alkoxy ι_6- Suitably R22 is H or alkyl ι_6. Suitably R24 is H, alkyl j.g, aryl, benzyl, heteroaryl, alkyl substituted by halogen or hydroxyl, or phenyl substituted by a member selected from the group consisting of halo, cyano, alkyl \.12, alkoxy \. , halosubstituted alkyl \. , alkylthio, alkylsulphonyl, or alkylsulfinyl; or R 2 and R24 may together with the nitrogen to which they are attached form a ring having 5 to 7 members, which members may be optionally replaced by a heteroatom selected from oxygen, sulfur or nitrogen. The ring may be saturated or contain more than one unsaturated bond. Preferably R 2 1 is NR 2 2R 2 4 and R22 and R24 are preferably hydrogen. When the R2, R3 and R5 cycloalkyl moieties is substituted by NR7R17 group, or NR7R17 Ci-io alkyl group, and the R7 and R17 are as defined in Formula (I), the substituent is preferably an amino, amino alkyl, or an optionally substituted pyrrolidinyl moiety. A preferred position of ring substitution on the C6 cycloalkyl moiety is the 4- position. When the cycloalkyl ring is di-substituted it is preferably di-substituted at the 4 position, such as in: wherein R* ' and R^' are independently the optional substituents indicated above for R2. Preferably, R*' and R^' are hydrogen, hydroxy, alkyl, substituted alkyl, optionally substituted alkyne, aryl, arylalkyl, NR7R17, and N(Rιo)C(O)Ri 1. Suitably, alkyl is Ci-4 alkyl, such as methyl, ethyl, or isopropyl; NR7R17 and NR7R17 alkyl, such as amino, methylamino, aminomethyl, aminoethyl; substituted alkyl such as in cyanomethyl, cyanoethyl, nitroethyl, pyrrolidinyl; aryl such as in phenyl; arylalkyl, such as in benzyl; optionally substituted alkyne, such as ethyne or propynyl; or together Ri ' and R^' are a keto functionality. In all instances herein where there is an alkenyl or alkynyl moiety as a substituent group, the unsaturated linkage, i.e., the vinylene or acetylene linkage is preferably not directly attached to the nitrogen, oxygen or sulfur moieties, for instance in OR3, or for certain R2 moieties. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. As used herein, "optionally substituted", unless specifically defined, shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted Ci-ioalkyl; Ci-io alkoxy, such as methoxy or ethoxy; S(O)malkyl, wherein m is 0, 1 or 2, such as methylthio, methylsulfinyl or methyl sulfonyl; halosubstituted Ci-io alkoxy; amino, mono & di-alkyl substituted amino, such as in the NR7R17 group; or where the R7R17 may together with the nitrogen to which they are attached cyclize to form a 5 to 7 membered ring which optionally includes an additional heteroatom selected from O/N/S; Ci-io alkyl, cycloalkyl, or cycloalkyl alkyl group, such as methyl, ethyl, propyl, isopropyl, t- butyl, etc. or cyclopropyl methyl; halosubstituted Ci-io alkyl, such CF3; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl moieties may also be substituted one to three times by halogen; hydroxy; hydroxy substituted alkyl; Cj-io alkoxy; S(O) m alkyl; amino, mono & di-substituted amino, such as in the NR7R17 group; alkyl, or CF3. The following terms, as used herein, refer to: • "halo" or "halogens", include the halogens: chloro, fluoro, bromo and iodo. • "Cι_ιoalkyl" or "alkyl" - both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, π-propyl, iso-propyl, π-butyl, sec-butyl, iso-b ty , tert- butyl, π-pentyl and the like. • "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like. • "cycloalkenyl" is used herein to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like. • "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl and the like. • "aryl" - phenyl and naphthyl. • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, indole, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole. • "heterocyclic" (on its own or in any combination, such as "heterocyclylalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, moφholine, tetrahydropyran, or imidazolidine. • "aralkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean Cj-4 alkyl as defined above attached to an aryl, heteroaryl or heterocyclic moiety as also defined herein unless otherwise indicate. • "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)2 moiety. • "aroyl" - a C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are note limited to benzyl and phenethyl. • "alkanoyl" - a C(O)Ci-io alkyl wherein the alkyl is as defined above. It is recognized that the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention. Exemplified compounds of Formula (I) include: 2-(4-Fluorophenyl)-3-(2-methylthiopyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-methoxy)pyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-phenoxy)pyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-aminopyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-(2-methylphenylamino)pyrimidin-4-yl) pyridine; or a pharmaceutically acceptable salt thereof. Synthetic Methods The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in Scheme I below. The synthesis provided for in these Schemes is applicable for producing compounds of Formula (I) having a variety of different Ri, R 2 , and R 4 groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. Once the nucleus has been established, further compounds of Formula (I) may be prepared by applying standard techniques for functional group interconversion all well known in this art. 2-Aryl-3-pyrimidin-4-yl pyridines were prepared from the corresponding 2-fluoro-3-methyl-pyridine by displacement of the fluorine with the aryl lithium reagent followed by oxidation of the 3-methyl group with KMnθ4 as described previously to afford the carboxylic acid 3 (Scheme 1) (see DuPriest, et al., J. Org. Chem. 1986, 51, 2021-2023). Conversion of the carboxylic acid to the methyl ketone 4b was effected by formation of the Weinreb amide 4a and subsequent reaction with MeMgCl. Synthesis of the 3-(pyrimidin-4-yl) pyridine was then be completed by the method first described by Brederick and co-workers, (see Bredereck, et al., Ber., Dtsch. Chem. Ges. 1964, 97, 3397-3406) and subsequently employed to prepare 4-heterocycle substituted pyrimidnes by others (see Sisko, J., J. Org. Chem. 1998, 63, 4529-4531; and Paul, R. et. al. J. Med. Chem. 1993, 36, 2716 - 2725). Thus the methyl ketone was reacted with dimethylformamide dimethyl acetal to form the enamine 4c, which can be reacted with urea, thiourea, isothiourea, guanidine, substituted guanidines, or formamidine to afford pyrimidines with varied substitution at the 2 position. A method, which has proven effective for synthesis of 2-S-alkyl substituted pyrimidines (see for instance, Adamset al., US Patent No.: 5,716,955) and used in example 1, involves formation of the 2-thiopyrimidine salt from the enamine and thiourea, in methanolic NaOMe, and capping the salt with methyl iodide to form sulfide 5a. Reaction of 5a with 2 equivalents of oxone afforded a mixture of sulfoxide 5b, and sulfone 5c. Displacement of the mixture pyrimidinyl sulfone and sulfoxide with nucleophiles such as methoxide and phenoxide afford 2-substituted pyrimidines such as 6 and 7 (Scheme 1). Scheme 1 - General methods for producing aryloxy and phenoxy pyrimidine substitu ne, Anilinyl pyrimidines 8a, 8b were prepared directly from the appropriate guanidine (Scheme 2). Alternatively 2-arylamino pyrimidines may be prepared from the sulfoxide 5b by displacement with aluminum salts of anilines as described in the patent literature (Adams et al., US Patent No.: 5,658,903). Scheme 2 - General methods for producing amino pyrimidine analogs of Formula (I) compounds. Further substitution on the pyridyl ring at R2, R3, R4, and R5, can be achieved from the appropriately substituted pyridines by substitution reactions in which the pyridine is regioselectively converted to either a nucleophile or an electrophile. Examples of this approach is depicted in Schemes 3 and 4 wherein the known bromo substituted pyridines 9 (Setliff, F.L, J.Chem. Eng. Data 1970, 590- 591) or 10 (Mallet, et al., J. Organomet. Chem, 1990, 383; 3, 319-332) can be converted to triaryl or diaryl alkyl substituted pyridine p38 kinase inhibitors using established procedures (see Miyaura, et al., Synth. Commun. 1981, 11, 513; Rieke, et al., Tetrahedron 1997, 53, 1925-1956; and Wagaw, et al., J, Org. Chem. 1996, 61, 7240-7241). Scheme 3 - Examples of general methods to produce tri-aryl substituted pyridine inhibitors of Formula (I). same steps as in schemes 1 and 2 Scheme 4 - Examples of general methods: Diaryl alkyl substituted pyridine p38 inhibitors. same steps as in schemes 1 and 2 1. Zn Suitable protecting groups for use in the present invention, are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981. Pharmaceutically acid addition salts of compounds of formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent. The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. Synthetic Examples The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents are highest available purity and all reactions run under anhydrous conditions in an argon atmosphere unless otherwise indicated. Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated. iH-NMR (hereinafter "NMR") spectra were recorded at 250 MHz using a Bruker AM 250 or Am 400 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal. Sat. indicates a saturated solution, eq indicates the proportion of a molar equivalent of reagent relative to the principal reactant. Flash chromatography is run over Merck Silica gel 60 (230 - 400 mesh). Using synthetic methods as described in the methods section herein, the following compounds have been prepared: Example 1 2-(4-Fluorophenyl)-3-(2-methylthiopyrimidin-4-yl) pyridine a) 2-(4-Fluorophenyl)-3-(N-methoxy-N-methylcarboxamido)pyridine (4a) 2-(Fluorophenyl)-3-pyridine carboxylic acid (3) (4.13grams (hereinafter "g"), 19.0 millimoles (hereinafter "mmol")) prepared from 2-fluoro-3-mefhyl pyridine in two steps as described in DuPriest, et al., J. Org. Chem. 1986, 51, 2021-2023. N,O-dimethylhydroxylamine hydrochloride (3.73g, 38.1 mmol), HOBt (5.14g, 38.1 mmol), CH2CI2 (190 milliliters (hereinafter "mL")), EDC Hydrochloride (4.38g, 22.8 mmol), and diisopropylethylamine (6.62mL, 38.1 mmol) were stirred together for about 20 hours (hereinafter "h"). The mixture was diluted with CH 2 C1 2 (250 mL), washed in succesion with satd aq citric acid, H 2 O, saturated aq NaHCO3, and sat'd. aqueous NaCl, dried (Na 2 SO4) and concentrated to afford a quanitative yield of 2-(4-Fluorophenyl)-3-(N-methoxy-N-methylcarboxamido)pyridine (4a) as a colorless oil which solidified to a white solid on standing in air for several days. MS ES+ m/z = 261 (MH+). b) 2-(4-Fluorophenyl)-3-acylpyridine (4b) The product of the previous experiment (l.Og, 3.8 mmol) in THF (20 mL) was cooled to 0° and MeMgCl (3M in THF) (4 mL, 12 mmol) was added dropwise (t<0°) and the resulting solution was slowly warmed to about 23°, and stirred 2h, and then carefully poured int EtOAc (150 mL) and H 2 O (50 mL). The phases were separated and the EtOAc was washed with H 2 O and then satd aq NaCl, dried (Na 2 SO4) and concentrated to afford 0.822g (100%) of 2-(4-Fluorophenyl)-3- acylpyridine (4a) as a light yellow oil. MS ES+ m/z = 216 (MH + ). c) 2-(4-Fluorophenyl)-3-(3-N.N-dimethylamino-trflni , -2-propene- 1 -one)pyridine (4c) The product of the previous example (0.822g , 3.8 mmol) and N,N- dimethylformamide dimethyl acetal (DMFDMA) (5mL) were combined and heated to DMFDMA reflux for 20 h. The solution was cooled to 23° and the DMFDMA was removed in vacuo to afford 2-(4-fluorophenyl)-3-(3-N,N-dimethylamino-trø«.s- 2-propene-l-one)pyridine (4c). MS ES+ m/z = 271 (MH+). d) 2-(4-Fluorophenyl)-3-(2-methylthiopyrimidin-4-yl) pyridine (5a) The product of the previous example, methanol (10 mL), thiourea (0.61g, 8 mmol), and 25% NaOMe in methanol (2.2 mL) was stirred under argon at 70° for 4 h. After cooling to 23° iodomethane (0.24 mL, 3.8 mmol) was be added dropwise and the mixture was stirred 2h. EtOAc and H 2 O was added and the organic phase separated, dried (Na 2 SO4), concentrated, flash chromatography with 0-1% MeOH in CH 2 C1 2 afforded 583mg (52% from 4b) of 2-(4-Fluorophenyl)-3-(2-methylthio- pyrimidin-4-yl) pyridine (5) as an ether soluble oil. A portion of 5 was treated with excess 1M HC1 in Et 2 O to afford a white precipitate which was washed throughly with Et2O, filtered and dried to afford the HC1 salt. MS ES+ m/z = 298 (MH+). Example 2 2-(4-Fluorophenyl)-3-(2-methoxy)pyrimidin-4-yl) pyridine (6) a) 2-(4-Fluorophenyl)-3-(2-methylsulfinyl)pyrimidin-4-yl) pyridine (5b) and 2-(4-Fluorophenyl)-3-(2-methylsulfonyl)pyrimidin-4-yl) pyridine (5c) A solution of the product of the previous example (583 mg, 1.96 mmol) in THF (30 mL) was cooled to about 0° and oxone (1.21g, 1.97 mmol) in H 2 O was added dropwise. The resulting mixture was warmed to 23° and stirred lόh.and then diluted with EtOAc (75 mL) and washed with 10% aq NaOH, H 2 O, satd aq NaCl, dried Na 2 SO4 and concentrated to afford 0.402g of a gummy white solid which was a mixture of aproximately 1 : 1 sulfoxide and sulfone. MS ES+ m/z = 314, 330 (MH+). b) 2-(4-Fluorophenyl)-3-(2-methoxy)pyrimidin-4-yl) pyridine The product of the previous example (0.2 g, 0.6 mmol) was added to THF (8 mL) and 25% NaOMe in MeOH (1 mL) was added and the resulting solution was stirred for 30 min and then poured into CH C1 2 (75 mL) and washed with H 2 O (2 X 25 mL) and then satd aq NaCl (25 mL), dried (Na 2 SO4) concentrated and filtered through a 5 g plug of silica with CH 2 C1 2 to afford 55mg (32%) of an oil which was dissolved in Et 2 O and treated with 1M HC1 in Et 2 O. The resulting white solid was filtered, washed with several portions of Et 2 O and dried in vacuo to afford the 2-(4- Fluorophenyl)-3-(2-methoxy)pyrimidin-4-yl) pyridine as a white solid. ES+ m/z = 283 (MH+). Example 3 2-(4-Fluorophenyl)-3-(2-phenoxy)pyrimidin-4-yl) pyridine Phenol (235 mg, 2.5 mmol) was added to 60% NaH (80 mg, 2 mmol) in dry THF (8 mL) and stirred 10 min. To the resulting solution was added the product of example 2a (0.2 g, 0.6 mmol) dissolved in THF (2 mL). After 30 min the reaction was poured into CH2CI2 (75 mL) and washed with H2O (2 X 25 mL) and then satd aq NaCl (25 mL), dried (Na2SO4) concentrated and filtered through a 5 g plug of silica with CH2CI2 to afford 65 mg (31%) of an oil which was dissolved in Et 2 O and treated with 1M HCl in Et 2 O. The resulting white solid was filtered, washed with several portions of Et O and dried in vacuo to afford the 2-(4-Fluorophenyl)-3- (2-phenoxy)pyrimidin-4-yl) pyridine as a white solid. ES+ m/z = 344 (MH + ). Example 4 2-(4-Fluorophenyl)-3-(2-aminopyrimidin-4-yl) pyridine Guanidine hydrochloride (0.76g, 8.0 mmol), n-propyl alcohol (5 mL) 25% NaOMe in MeOH (1.8 mL, ca 8 mmol) and the product of example 1(d) (from 3.8 mmol of the product of example 1 (a)) were combined and heated to n-propyl alcohol reflux for 16 h. The reaction was cooled, diluted with CH,C1, (200 mL) and washed with 10% aq NaOH, H 2 O, and saturated aq NaCl, dried (Na 2 SO 4 ), concentrated and dried in vacuo for 16 h to remove residual n-propanol. Flash chrmoatography (200 mL silica, 0-2% MeOH in CH,C1 2 ) and trituration with Et,O afforded 0.624g (62% (from the product of example 1 (a))). MS ES+ = 267 (MH+) Example 5 2-(4-Fluorophenyl)-3-(2-(2-methylphenylamino)pyrimidin-4-yl) pyridine a) 2-Methylphenylguanidine o-Toluidine (Aldrich) (4.28g, 40 mmol) was combined with 1M HCl in Et 2 O (40 mL, 40 mmol) and concentrated to afford the hydrochloride as a white solid. Cyanamide (1.9 g, 46 mmol) and EtOH (50 mL) were added to the solid and the mixture was heated to EtOH reflux for 16 h. The EtOH was removed in vacuo, and H 2 O (300 mL) was added to the residue and solid HCl salt was filtered off. MS ES+ m/z = 150 (MH+). b) 2-(4-Fluorophenyl)-3-(2-(2-methylphenylamino)pyrimidin-4-yl) pyridine The product of the previous example (740, 4.0 mmol), n-propanol (5 mL) and the product of example 1(b) (from 3.8 mmol of the product of example 1(a)) were combined and heated to n-propanol reflux for 3 days (still minor amounts of the product of example 1(b) based on tic), diluted with CH,C1 2 , and washed with 10% aq NaOH, H 2 O, and satd aq NaCl, dried (Na,SO 4 ), and the volatiles were removed in vacuo. The residue was flash chromatographed (200 mL silica, 0 - 1 % MeOH in CH,C1 2 ) to afford a gummy solid. The gum was dissolved in Et,O (25 mL) and 1M HCl in Et 2 O (10 mL, 10 mmol) was added. The mixture was stirred 5 min and then was filtered and the solid HCl salt was washed with Et 2 O and dried in vacuo to afford 735 mg (45% of dihydrochloride (from the product of example 1(a))). MS ES+ = 357 (MH+) METHODS OF TREATMENT The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages. As used herein, unless specifically indicated, compounds of Formula (I) also refers to and includes compounds of Formula (II). Compounds of Formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF and are therefore of use in therapy. IL- 1, IL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states. Accordingly, the present invention provides a method of treating a cytokine- mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy. These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme. Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I). This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX-1 thereby inhibiting prostoglandins essential for cytoprotective effects. Thus inhibition of these pro-inflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states. Most notably these inflammatory mediators, in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema. This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain. Compounds of Formula (I) or a pharmaceutically acceptable salt thereof, are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme. Accordingly, the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme. In particular, compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and/or macrophages. Accordingly, in another aspect, this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. There are many disease states in which excessive or unregulated IL- 1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, stroke, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resoφtion, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes, pancreatic β cells and Alzheimer's disease. Use of a CSAID for the treatment of CSBP mediated disease states, can include, but not be limited to neurodegenerative diseases, such as Alzheimer's disease (as noted above), Parkinson's disease and multiple sclerosis, etc.. In a further aspect, this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, cerebral malaria, chronic pulmonary inflammatory disease and chronic obstructive pulmonary disease, silicosis, pulmonary sarcoisosis, bone resoφtion diseases, such as osteoporosis, cardiac, brain and renal reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, brain infections including encephalitis (including HIV-induced forms), cerebral malaria, meningitis, ischemic and hemorrhagic stroke, cachexia secondary to infection or malignancy, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, inflammatory bowel disease, Crohn's disease, ulcerative colitis and pyresis. Compounds of Formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of Formula (1). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV- 3, Cytomegalovirus (CMV), Influenza, adenovirus and the Heφes group of viruses, such as but not limited to, Heφes Zoster and Heφes Simplex. Accordingly, in a further aspect, this invention relates to a method of treating a mammal afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections. The compounds of Formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, contact dermititis, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. Periodontial disease has also been implimented in cytokine production, both topically and sytemically. Hence use of compounds of Formula (I) to control the inflammation associated with cytokine production in such peroral diseases such as gingivitis and periodontitis is another aspect of the present invention. Compounds of Formula (I) have also been shown to inhibit the production of IL-8 (Interleukin-8, NAP). Accordingly, in a further aspect, this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases are characterized by massive neutrophil infiltration such as, psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8 production which is responsible for the chemotaxis of neutrophils into the inflammatory site. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutrophil infiltration. The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-6, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state. Abnormal levels of IL-1, IL-6, IL-8 or TNF, for instance in the context of the present invention, constitute: (i) levels of free (not cell bound) IL-1, IL-6, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-6, IL-8 or TNF; or (iii) the presence of IL-1, IL-6, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL- 1 , IL-6, IL-8 or TNF, respectively, is produced. The discovery that the compounds of Formula (I) are inhibitors of cytokines, specifically IL-1, IL-6, IL-8 and TNF is based upon the effects of the compounds of Formulas (I) on the production of the IL-1, IL-8 and TNF in in vitro assays which are described herein. As used herein, the term "inhibiting the production of IL-1 (IL-6, IL-8 or TNF)" refers to: a) a decrease of excessive in vivo levels of the cytokine (IL- 1 , IL-6, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL- 1, IL-6, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels. As used herein, the term "TNF mediated disease or disease state" refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease stated mediated by TNF. As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B -lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNF-β). As used herein, the term "cytokine interfering" or "cytokine suppressive amount" refers to an effective amount of a compound of Formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production. As used herein, the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of a HIV-infected human" is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell-mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. As TNF-β (also known as lymphotoxin) has close structural homology with TNF-α (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-α and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise. A member of the MAP kinase family, alternatively termed CSBP, p38, or RK, has been identified independently by several laboratories recently [See Lee et al., Nature, Vol. 300 n(72), 739-746 (1994)]. Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin- 1 and tumor necrosis factor. The cytokine biosynthesis inhibitors, of the present invention, compounds of Formula (I), have been determined to be potent and selective inhibitors of CSBP/p38 RK kinase activity. These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages. In addition to those diseases already noted herein, treatment, including prophylaxis, of stroke, neurotrauma/CNS head injury, cardiac, brain and renal reperfusion injury, thrombosis, glomerulonephritis, diabetes and pancreatic β cells, multiple sclerosis, muscle degeneration , eczema, psoriasis, sunburn, and conjunctivitis are also included. The cytokine inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies. Most notable are its effectiveness in the collagen-induced arthritis model and inhibition of TNF production in the endotoxic shock model. In the latter study, the reduction in plasma level of TNF correlated with survival and protection from endotoxic shock related mortality. Also of great importance are the compounds effectiveness in inhibiting bone resoφtion in a rat fetal long bone organ culture system. Griswold et al., (1988) Arthritis Rheum. 31:1406-1412; Badger, et al., (1989) Circ. Shock 27, 51-61; Votta et al., (1994) vitro. Bone 15, 533-538; Lee et al., (1993). B Ann. N. Y. Acad. Sci. 696, 149-170. It is also recognized that both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of common cold and exacerbation of asthma associated with HRV infection (Turner et al. (1998), Clin. Infec. Dis., Vol 26, p 840; Teren et al. (1997), Am J Respir Crit Care Med vol 155, pl362; Grunberg et al. (1997), Am J Respir Crit Care Med 156:609 and Zhu et al, J Clin Invest (1996), 97:421). It has also been demonstrated in vitro that infection of pulmonary epithelial cells with HRV results in production of IL-6 and IL-8 (Subauste et al., J. Clin. Invest. 1995, 96:549.) Epithelial cells represent the primary site of infection of HRV. Therefore another aspect of the present invention is a method of treatment to reduce inflammation associated with a rhinovirus infection, not necessarily a direct effect on virus itself. Another aspect of the present invention is to the novel use of these CSBP/cytokine inhibitors for the treatment of chronic inflammatory or proliferative or angiogenic diseases which are caused by excessive, or inappropriate angiogenesis. Chronic diseases which have an inappropriate angiogenic component are various ocular neovasularizations, such as diabetic retinopathy and macular degeneration. Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore cytokine inhibitors will be of utility in the blocking of the angiogenic component of these disease states. The term "excessive or increased proliferation of vasculature inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases. The term "inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis. Preferred CSPB mediated diseases for treatment include, but are not limited to psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, cerebral malaria, meningitis, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resoφtion disease, osteoporosis, restenosis, cardiac reperfusion injury, brain and renal reperfusion injury, chronic renal failure, thrombosis, glomerularonephritis, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenrative disease, multiple sclerosis, muscle degeneration, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, rhinovirus infection, peroral disease, such as gingivitis and periodontitis, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis. In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be Formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incoφorating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax. A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25 mg. to about lg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension. Compounds of Formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration. Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation. Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil. Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incoφorate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included. Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100° C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol. Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques. For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15 mg. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15 mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. The invention will now be described by reference to the following biological examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. BIOLOGICAL EXAMPLES The cytokine-inhibiting effects of compounds of the present invention were determined by the following in vitro assays: Assays for Interleukin- 1 (IL-1), Interleukin-8 (IL-8 ), and Tumour Necrosis Factor (TNF) are well known in the art, and may be found in a number of publications, and patents. Representative suitable assays for use herein are described in Adams et al., US 5,593,992, whose disclosure is incoφorated by reference in its entirety. Interleukin - 1 (IL-1) Human peripheral blood monocytes are isolated and purified from either fresh blood preparations from volunteer donors, or from blood bank buffy coats, according to the procedure of Colotta et al, J Immunol, 132, 936 (1984). These monocytes (1x10^) are plated in 24-well plates at a concentration of 1-2 million/ml per well. The cells are allowed to adhere for 2 hours, after which time non-adherent cells are removed by gentle washing. Test compounds are then added to the cells for lh before the addition of lipopolysaccharide (50 ng/ml), and the cultures are incubated at 37°C for an additional 24h. At the end of this period, culture supernatants are removed and clarified of cells and all debris. Culture supernatants are then immediately assayed for IL-1 biological activity, either by the method of Simon et al., J. Immunol. Methods, 84, 85, (1985) (based on ability of IL-1 to stimulate a Interleukin 2 producing cell line (EL-4) to secrete IL-2, in concert with A23187 ionophore) or the method of Lee et al., J. ImmunoTherapy, 6 (1), 1-12 (1990) (ELISA assay). In vivo TNF assay: (1) Griswold et al., Drugs Under Exp. and Clinical Res..XIX (6), 243-248 (1993); or (2) Boehm, et al, Journal Of Medicinal Chemistry 39, 3929-3937 (1996) whose disclosures are incoφorated by reference herein in their entirety. LPS -induced TNFα Production in Mice and Rats In order to evaluate in vivo inhibition of LPS-induced TNFα production in rodents, both mice and rats are injected with LPS. Mouse Method Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO 2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNFα by ELISA. Rat Method Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 3.0 mg/kg intraperitoneally. The rats are killed by CO 2 inhalation and heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection. The blood samples are centrifuged and the plasma collected for analysis by ELISA for TNFα levels. ELISA Method TNFα levels were measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incoφorated by reference in its entirety herein, using a hamster monoclonal antimurine TNFα (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody. For detection, a peroxidase-conjugated goat antirabbit antibody (Pierce, Rockford, IL) was added, followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 1% urea peroxide). TNFα levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNFα (Genzyme). LPS-Stimulated Cytokine Production in Human Whole Blood Assay: Test compound concentrations were prepared at 10 X concentrations and LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes. Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes were centrifuged at 5000 φra for 5 minutes in a TOMY microfuge, plasma was withdrawn and frozen at -80 C. Cytokine measurement: IL-I and/or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL- 1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis. Prostoglandin endoperoxide synthase-2 (PGHS-2) assay: This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes. A suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is incoφorated herein by reference. CSBP Kinase Assay: This assay measures the CSBP-catalyzed transfer of 32p from [a-32p]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPL7PSGEAPNQALLR (residues 661-681). (See Gallagher et al., "Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSPB Kinase", BioOrganic & Medicinal Chemistry, to be published 1996). Kinase reactions (total volume 30 ul) contain: 25 mM Hepes buffer, pH 7.5; 10 mM MgCl 2 ; 170 uM ATPO); 10 uM Na ortho vanadate; 0.4 mM T669 peptide; and 20-80 ng of yeast-expressed purified CSBP2 (see Lee et al., Nature 300, n(72), 739-746 (Dec. 1994)). Compounds (5 ul from [6X] stock( 2 )) are pre-incubated with the enzyme and peptide for 20 min on ice prior to starting the reactions with 32P/MgATP. Reactions are incubated at 30 °C for 10 min and stopped by adding 10 ul of 0.3 M phosphoric acid. 32P-labeled peptide is separated on phosphocellulose (Wattman, p81) filters by spotting 30 ul reaction mixture. Filters are washed 3 times with 75 mM phosphoric acid followed by 2 washes with H 2 O, and counted for 32P. ( 1) The Km of CSBP for ATP was determined to be 170 uM. Therefore, compounds screened at the Km value of ATP. (2) Compounds are usually dissolved in DMSO and are diluted in 25 mM Hepes buffer to get final concentration of DMSO of 0.17%. Compounds of Formula (I), exemplified by Examples 1 to 5 herein have been determined to be active in this assay for inhibition having an IC50 of <50uM. TNF-α in Traumatic Brain Injury Assay This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- α is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- α plays an important role in both the acute and regenerative response to CNS trauma. A suitable assay may be found in WO 97/35856 whose disclosure is incoφorated herein by reference. CNS Injury model for IL-β mRNA This assay characterizes the regional expression of interleukin- lβ (IL-lβ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-lβ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-lβ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury. A suitable assay may be found in WO 97/35856 whose disclosure is incoφorated herein by reference. Angiogenesis Assay: Described in WO 97/32583, whose disclosure is incoφorated herein by reference, is an assay for determination of inflammatory angiogenesis which may be used to show that cytokine inhibition will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels. All publications, including but not limited to patents and patent applications, cited in this specification are herein incoφorated by reference as if each individual publication were specifically and individually indicated to be incoφorated by reference herein as though fully set forth. The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims: What is Claimed Is: 1. A compound of the formula wherein R\ is X-R a . optionally substituted Cι_4 alkyl, halogen, hydroxyl, optionally substituted Cj_4 alkoxy, optionally substituted C1.4 alkylthio, optionally substituted .^ alkylsulfinyl, CH 2 OR^ 2 , amino, mono and di- C\. alkyl substituted amino, N(Rιo)C(O)Rb, N(Rιo)S(O) 2 Rd. or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; Y is CH or N; X is oxygen, sulfur or NH; R a is Cj_6 alkyl, aryl, arylC 6 alkyl, heterocyclic, heterocyclylC \. alkyl, heteroaryl, or heteroarylC ! _g alkyl moiety, wherein each of these moieties may be optionally substituted; Rb is hydrogen, Cj.g alkyl, 03.7 cycloalkyl, aryl, arylCι.4 alkyl, heteroaryl, heteroarylC 1 _4 alkyl, heterocyclyl, or heterocyclylC 1-4 alkyl; R ( j is C 1-6 alkyl, C3.7 cycloalkyl, aryl, arylC _4 alkyl, heteroaryl, heteroarylC \.4 alkyl, heterocyclyl, or heterocyclylC 1-.4 alkyl; n is 0, or an integer having a value of 1 to 10; v is 0, or an integer having a value of 1 or 2; m is 0, or the integer having a value of 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; R 2 , R3 and R5, are independently hydrogen, (CRκ)R 2 3)nOR9> (C ioR-23)nORl 1> Cι_ιo alkyl, halo-substituted C J . ^Q alkyl, C 2 _JQ alkenyl, C 2 _ι o alkynyl, C3.7 cycloalkyl, C3_.7cycloalkylC1. 0 alkyl, C5_7 cycloalkenyl, C5.7 cycloalkenyl Cι _ιo alkyl, aryl, arylC io alkyl, heteroaryl, heteroarylC \ .\Q alkyl, heterocyclyl, heterocyclylC .\Q alkyl, (CRιoR 2 3)r_S(O) m Ri8, (CR 10 R 2 3)nNHS(O) 2 Ri8, (CRι 0 R 2 3)nNRi 3 Rl4> (CRι 0 R 23 )nNO 2 , (CRi 0 R 3 ) n CN, (CRι 0 R 3 )n S(0)mNR 13 Rι 4) (CRι 0 R 23 )nC(Z)Rι ι, (CRιoR 2 3) n OC(Z)R 1 1 , (CRι 0 R 2 3)nC(Z)OR n , (CR 10 R 2 3)nC(Z)NR 13 R 1 4 ! (CR 10 R 23 ) n C(Z)NR 1 !OR 9 , (CR 10 R 23 ) n NRioC(Z)R 1 1 , (CRιoR23)nNRlθC(Z)NR 13 R 1 4, (CRιoR23)nN(OR 6 )C(Z)NRi3R 1 4, (CR 10 R 2 3)nN(OR 6 )C(Z)R 1 1 , (CR 10 R 2 3)nC(=NOR 6 )R 1 1 , (CRi 0 R 2 3) n NRl0C(=NRi9) NRι 3 R 14 , (CRι 0 R 2 3)nOC(Z)NR 13 R 1 4, (CRi 0 R 23 )nNRl0C(Z) NR 13 R 14 , (CR 10 R 2 3) n NRlθC(Z)OR 10 , 5-(R 18 )-l,2,4- oxadizaol-3-yl or 4-(Rι 2 )-5-(Rι 8 Ri9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; and wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or heteroaryl, which is optionally substituted by one to three substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Rj7, C(Z)ORιg, (CR!oR 2 o) v COR 12 , SR5', S(O)R5', ORι 2 , halo-substituted-C^ alkyl, C^alkyl, ZC(Z)Rι 2 , NRιøC(Z)Ri6, or (CRJOR^ NRIOR^ and which, for other positions of substitution, is halogen, cyano, nitro, phenyl, C(Z)NRι 3R14, C(Z)OR 2 5, (CRιoR θ)m"COR 2 5, S(O) m R 2 5, OR 2 5, halosubstituted-Cι.4 alkyl, CJ. JQ alkyl, ZC(Z)R 5, optionally substituted phenyl, (CR 10 R 2 θ)m"NRlθC(Z)R 25 , NR 10 S(O) m 'R 8 , NR 10 S(O) m 'NR 7 R 17 , or (CR 10 R 2 0)m"NRl 3 Rl4; R5' is hydrogen, Cμ4 alkyl, C 2 _4 alkenyl, C2-.4 alkynyl or NR7R17, excluding the moieties SR5 » being SNR7R 17 and SOR5 » being SOH; Rg is hydrogen, a pharmaceutically acceptable cation, CI . JQ alkyl, 03,7 cycloalkyl, aryl, arylCι _4 alkyl, heteroaryl, heteroarylC {.4 alkyl, heterocyclic, aroyl, or \.\Q alkanoyl; R7 and R17 is each independently selected from hydrogen or C^_4 alkyl or R7 and Rj7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; Rg is Cj.io alkyl, halo-substituted alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C5.7 cycloalkenyl, aryl, arylCι_ιo alkyl, heteroaryl, heteroarylC \.\Q alkyl, (CR 10 R 20 ) n ORl l , (CRι 0 R 2 o)nS(O) m Rι 8 , (CRι 0 R 2 θ)nNHS(O) 2 R 18 , or (CRιoR 2 θ)nNRl3Rl4. wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted; R9 is hydrogen, C(Z)RJ I or optionally substituted C io alkyl, S(O)2Rι 8 , optionally substituted aryl or optionally substituted arylCj_4 alkyl; R|o and R20 is e ch independently selected from hydrogen or C^_4 alkyl; Rj 1 is hydrogen, C I _IQ alkyl, 03.7 cycloalkyl, heterocyclyl, heterocyclyl CJ.JO alkyl, aryl, arylCι_ιo alkyl, heteroaryl or a heteroarylC \. \Q alkyl moiety, wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl or heterocyclylalkyl moieties may be optionally substituted; R 12 is hydrogen or R 1 g; Rl3 and R14 is each independently selected from hydrogen or optionally substituted Cj_4 alkyl, optionally substituted aryl or optionally substituted aryl-Cι_4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; Rj5 is hydrogen, Cj_4 alkyl or C(Z)-Cι_4 alkyl; Rig is Cι_4 alkyl, halo-substituted-Cι.4 alkyl, or 03,7 cycloalkyl; Rj 8 is CJ.JO alkyl, 03.7 cycloalkyl, heterocyclyl, aryl, arylCi .jQ alkyl, heterocyclyl, heterocyclyl-Cι _ιo alkyl, heteroaryl or a heteroarylalkyl moiety, wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclyl or heterocyclylalkyl moieties may be optionally substituted; R19 is hydrogen, cyano, Cj_4 alkyl, 03.7 cycloalkyl or aryl; R23 is hydrogen, C . alkyl, C3.7 cycloalkyl, aryl, arylCj_4 alkyl, heteroaryl, heteroarylC ι_4 alkyl, heterocyclyl, or a heterocyclylC] .4 alkyl moiety, all of which moieties may be optionally substituted; R25 is heterocyclyl, heterocyclylC \. \Q alkyl or R 8 ; Z is oxygen or sulfur; or a pharmaceutically acceptable salt thereof. 2. The compound according to Claim 1 wherein Ri is an optionally substituted 4-pyrimidine. 3. The compound according to Claim 2 wherein the substituent is X-R a or amino. 4. The compound according to Claim 3 wherein R a is alkyl, or an optionally substitued aryl. 5. The compound according to Claim 1 wherein R4 is an optionally substituted phenyl. 6. The compound according to Claim 5 wherein the phenyl is substituted one or more times independently by halogen, SR5, S(O)R5, OR12, halo-substituted-Ci-4 alkyl, or Ci-4 alkyl. 7. The compound according to Claim 1 wherein R2 is hydrogen. 8. The compound according to Claim 1 wherein R3 is hydrogen. 9. The compound according to Claim 1 wherein R5 is hydrogen. 10. The compound according to Claim 1 wherein R2, R3 and R5 are hydrogen. 11. The compound according to Claim 1 which is 2-(4-Fluorophenyl)-3-(2-methylthiopyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-methoxy)pyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-phenoxy)pyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-aminopyrimidin-4-yl) pyridine; 2-(4-Fluorophenyl)-3-(2-(2-methylphenylamino)pyrimidin-4-yl) pyridine; or a pharmaceutically acceptable salt thereof. 12. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 11 and a pharmaceutically acceptable carrier or diluent. 13. A method of treating a CSBP/RK/p38 kinase mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) according to any one of Claims 1 to 11. 14. The method according to Claim 13 wherein the mammal is afflicted with a CSBP/RK/p38 kinase mediated disease which is psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, cerebral malaria, meningitis, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resoφtion disease, osteoporosis, restenosis, cardiac reperfusion injury, brain and renal reperfusion injury, chronic renal failure, thrombosis, glomerularonephritis, diabetes, diabetic retinopathy, macular degeneration, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, neurodegenrative disease, multiple sclerosis, muscle degeneration, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, rhinovirus infection, gingivitis, periodontitis, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis.

Inventors: ADAMS JERRY L, BOEHM JEFFREY C, ADAMS, JERRY, L., BOEHM, JEFFREY, C.
Applicants: ADAMS JERRY L, BOEHM JEFFREY C, SMITHKLINE BEECHAM CORP, ADAMS, JERRY, L., BOEHM, JEFFREY, C., SMITHKLINE BEECHAM CORPORATION
Application year: 2000
Main classification: A61K31
IPC codes: A61K31, A61P1, A61P3, A61P7, A61P9, A61P11, A61P13, A61P17, A61P19, A61P21, A61P25, A61P27, A61P29, A61P31, A61P33, A61P35, A61P37, C07D401